

Earnings miss expectations, with margin pressure and absence of one-offs weighing on profitability

Saudi German Health reported a weak Q1-26, with net profit declining sharply by 83.9% Y/Y (-31.9% Q/Q) to SAR 26mn, missing both internal and consensus estimates. While revenues posted modest 4.3% Y/Y growth, profitability was significantly impacted by gross margin compression—driven by new physician hires, lower contribution from high-margin MoH business, and higher depreciation—alongside the absence of last year’s one-off land sale gain of SAR 114mn. Operating performance also lagged expectations despite some normalization in opex, reflecting ongoing cost pressures and competitive intensity, supporting a Neutral stance given limited near- to medium-term upside

- **Saudi German Health posted a net profit** of SAR 26mn in Q1-26, reflecting a significant 83.9% decline on a Y/Y basis, while also declining by 31.9% sequentially. The modest Y/Y topline growth during the quarter was offset by the gross margin compression. Overall performance remained below expectations, falling short of AJBC’s estimate of SAR 30.3mn by 15.2% and the consensus forecast of SAR 29.5mn by 12.7%. Apart from company’s underperformance on gross profit level, the majority of Y/Y decline in earnings also came from last year’s one-off gain of SAR 114mn on land sale. Adjusting for this one-off gain, 1Q-26 earnings would have been declined by 44.2% on Y/Y basis.
- **Revenues** grew by 4.3% Y/Y (-5.3% Q/Q) to SAR 765mn in Q1-26 (-1.2% deviation to AJBC estimate of SAR 775mn). Within the segments, Outpatients segment posted highest topline growth of 5.5% Y/Y, followed by the In-Patient services segment growth of 3.6%, whereas Pharmacies segment has shown decline in the revenues by 3.2%.
- **Gross profit** declined by 9.1% Y/Y to SAR 254mn in Q1-26 (-12.4% deviation to AJBC estimate of SAR 290mn). Gross margin contracted by 494 bps Y/Y (-102bps Q/Q) to 33.2% (-425bps deviation to AJBC estimate of 37.5%). The contraction in gross margins were primarily driven by new physicians’ hires, lower contribution from high-margin MoH business, and higher depreciation expense associated with capacity expansions. Consequently, gross margins on In-patients and Outpatients segments contracted to 37.2% (Last Year: 42.1%) and 30.9% (Last year: 38.1%) respectively.
- **Operating profit** declined by 21.1% Y/Y and 7.9% Q/Q to SAR 80mn in Q1-26 (-20.6% deviation to AJBC estimate of SAR 101mn). Operating margin stood at 10.5% in Q1-26, down 338bps Y/Y (-29bps Q/Q) and 256bps below AJBC estimate of 13.0%. OPEX-to-sales normalizes by 156bps Y/Y to 22.8%, due to 3.6% decline in the Selling & Distribution expenses during the quarter.

AJBC view and valuation: Saudi German’s underperformance during the quarter reflects the underlying competition dynamics and cost pressures arising from new hirings which still lags in terms of revenue monetization. Despite this, the stock trades at a 2026E P/E of 28.8x versus the sector average of c.21.0x, implying a c.37% premium, which we believe is not fully justified given the current earnings trajectory. Considering this weak near to midterm earnings outlook and limited valuation headroom, we reiterate our **“Neutral”** rating on the stock with the TP of **SAR 41.5/share**.

Results Summary

SAR mn	Q1-25	Q4-25	Q1-26	Change Y/Y	Change Q/Q	Deviation from AJBC Estimates
Revenue	734	809	765	4.32%	-5.38%	-1.26%
Gross profit	280	277	254	-9.18%	-8.21%	-12.47%
Gross margin	38.17%	34.25%	33.23%	-	-	-
EBIT	102	87	80	-21.18%	-7.96%	-20.65%
Net profit	160	38	26	-83.95%	-31.99%	-15.18%
EPS	1.74	0.41	0.28	-	-	-

Source: Company Reports, Aljazira Capital Research

Recommendation	Neutral
Target Price (SAR)	41.5
Upside / (Downside)*	10.7%

Source: Tadawul *prices as of 3rd of May 2026

Key Financials

Financials (in SAR mn, unless specified)	FY23	FY24	FY25
Revenue	2,653	2,883	3,103
Growth %	23.3%	8.7%	7.6%
Gross Profit	1,014	1,114	1,160
EBIT	324	441	373
Net Profit	17	282	302
Growth %	-77.3%	1555.1%	7.0%
EPS	0.19	3.06	3.28
DPS	0.00	0.50	0.50

Source: Company reports, Aljazira Capital Research

Key Ratios

	FY23	FY24	FY25
GP Margin	38.2%	38.6%	37.4%
EBIT Margin	12.2%	15.3%	12.0%
Net Margin	0.6%	9.8%	9.7%
P/E (x)	450.0	22.4	15.7
P/B (x)	5.8	3.9	2.5
EV/EBITDA (x)	20.2	13.6	12.0
Div Yield (%)	0.0%	0.7%	1.0%


Source: Company reports, Aljazira Capital Research

Key Market Data

Market Cap(bn)	3.4
YTD%	15.11%
52 week (High)/(Low)	71.8/28.6
Share Outstanding (mn)	92

Source: Company reports, Aljazira Capital Research

Price Performance



Source: Tadawul, Aljazira Capital Research

Senior Equity Analyst

Abdullah Umer

+966 54 796 3867

a.umer@aljaziracapital.com.sa

RESEARCH DIVISION

Director - Head of Sell-Side Research
Jassim Al-Jubran
+966 11 2256248
j.aljabran@aljazaracapital.com.sa

RESEARCH
DIVISION

Aljazira Capital, the investment arm of Bank Aljazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. Aljazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. Aljazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, Aljazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING
TERMINOLOGY

1. Overweight: This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. Underweight: This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. Neutral: The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. Suspension of rating or rating on hold (SR/RH): This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of securities, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. Some securities maybe, by nature, of low volume/trades, or may become so, unexpectedly in special circumstances, and this might increase the risk on the investor. Some fees might be levied on some investments in securities. Aljazira Capital, its employees, one or more of its board members, its affiliates, or its clients may have investments in the securities or assets referred to in this report. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.